Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer
Abstract Ovarian cancer is the deadliest gynecological malignancy, owing to its late-stage diagnosis and high rates of recurrence and resistance following standard-of-care treatment, highlighting the need for novel treatment approaches. Through an unbiased drug screen, we identified the kinase inhib...
Saved in:
| Main Authors: | Esther P. B. Rodman, Michael J. Emch, Xiaonan Hou, Archit Bajaj, Nicole A. Pearson, August J. John, Yamillie Ortiz, Adam D. Bass, Saloni Singh, Gustavo Baldassarre, Scott H. Kaufmann, S. John Weroha, John R. Hawse |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-00947-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
JAK/STAT signaling in hepatocellular carcinoma
by: Justin Jit Hin Tang, et al.
Published: (2020-03-01) -
JAK-STAT Signaling in Autoimmunity and Cancer
by: Parveen S, et al.
Published: (2025-05-01) -
Exploration of JAK/STAT pathway activation in ulcerative colitis reveals sex-dependent activation of JAK2/STAT3 in the inflammatory response
by: Cristina Calviño-Suárez, et al.
Published: (2025-07-01) -
NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma
by: Gustavo Nery de Queiroz, et al.
Published: (2024-12-01) -
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons
by: Naseema Gangat, et al.
Published: (2025-05-01)